

AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph appearing at page 2, line 27 to page 3, line 1, with the following amended paragraph:

As a result of zealous endeavor of the inventors of the present invention to solve the foregoing objects, the inventors found that $[[a]]$ compounds having a dicarba-*closo*-dodecaborane structure represented by the following general formula (I) has superior activity as a ligand of a nuclear receptor such as the retinoic acid receptor and exhibits a superior therapeutic effect as a differentiation-inducing agent for the treatment of leukemia. The present invention was achieved on the basis of these findings.